Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor

Anatol J Cardiol. 2019 Jun;22(1):46-48. doi: 10.14744/AnatolJCardiol.2019.67124.

Authors

Marie-Camille Soucy-Giguere¹, Éric Charbonneau², Alexandre Cinq Mars¹, Michelle Dubois³, Mario Sénéchal¹

Affiliations

¹ Department of Cardiology, Quebec Heart and Lung Institute, Laval University; Quebec-Canada.
² Department of Cardiovascular Surgery, Quebec Heart and Lung Institute, Laval University; Quebec-Canada.
³ Research Center, Quebec Heart and Lung Institute, Laval University; Quebec-Canada.

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Arthritis / drug therapy
Arthritis / etiology
Cardiomyopathy, Dilated / complications
Cardiomyopathy, Dilated / diagnosis*
Cardiomyopathy, Dilated / drug therapy
Cardiotonic Agents / therapeutic use
Crohn Disease / complications
Etanercept / therapeutic use
Female
Furosemide / therapeutic use
Heart Failure / chemically induced*
Heart Failure / therapy*
Heart-Assist Devices*
Humans
Infliximab / adverse effects*
Infliximab / therapeutic use
Milrinone / therapeutic use
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Cardiotonic Agents
Tumor Necrosis Factor-alpha
Furosemide
Infliximab
Milrinone
Etanercept